Further categorizing AML patients based on the expression levels of SEC61A1 and FLT3, we classified them into three groups (SEC61A1low with FLT3low, SEC61A1low and FLT3high or SEC61A1high with FLT3low, and SEC61A1high with FLT3high). This evidence concerns the gene SEC61A1 and acute myeloid leukemia.